Trinity Biotech Plans 1-for-30 Reverse ADS Split to Meet Nasdaq

Trinity Biotech plans a 1-for-30 reverse ADS split, changing from 1 ADS for 20 Class A shares to 1 ADS for 600 Class A shares, to regain Nasdaq’s $1 minimum bid price and attract a broader investor base, with the move taking effect around July 24, 2026. The announcement followed by a dash in premarket trading and comes amid concerns over the company’s weak finances and profitability, which have kept the stock trading at depressed levels.